Literature DB >> 29353018

Nebulization effects on structural stability of bacteriophage PEV 44.

Ariel Astudillo1, Sharon Shui Yee Leung1, Elizabeth Kutter2, Sandra Morales3, Hak-Kim Chan4.   

Abstract

Reduced infectivity of phage due to the nebulization process has been reported previously, but no visual evidence on structural change upon nebulization has been established, or whether these structural changes can be attributed to the titer reduction. In this study, transmission electron microscopy (TEM) was employed to assess the impact of three different types of nebulizers, air-jet, vibrating-mesh and static-mesh nebulizers, on the structural stability of a Myoviridae phage, PEV44, active against Pseudomonas aeruginosa. The morphology of the phage in the nebulized samples was categorized into two groups: "whole" (the capsid and tail held together) and "broken" (the capsid separated from the tail) phages. The "whole" phage group was further divided into three sub-groups: (1) intact, (2) contracted tail and (3) empty capsid. The starting stock suspension was found to contain considerable portions of "broken" phages (35.5 ± 6.7%), "whole" phages with contracted tails (9.9 ± 5.4%) and empty capsids (19.3 ± 8.9%). The fraction of "broken" phages was significantly increased after nebulization, with the air-jet nebulizer (83%) being more pronounced than the mesh type nebulizers (50-60%). While the amount of intact phages (2-10%) and whole phages with contracted tails (0-3%) were significantly decreased, the proportion of phages with empty capsids (15-36%) were not significantly different. Phages with broken features obtained by TEM quantification were 92.9 ± 3.2%, 74.8 ± 10.4% and 71.2 ± 11.0% for the jet, vibrating-mesh and static-mesh nebulizers, respectively. These results were found to be comparable with the titer loss obtained by the conventional plaque assay results. The in vitro aerosol performance and viable phage delivery of the three nebulizers was also assessed. The Omron nebulizer achieved a significantly higher viable respirable fraction (VRF) than the SideStream and Aeroneb Go (15.1 ± 5.8%, 2.4 ± 2.0%, 4.1 ± 2.7% respectively). In conclusion, this study identified various changes in the phage structure and viability of phage from different types of nebulizers. Understanding these effects and the phage tolerance to nebulization stresses can potentially improve our choice of the delivery method for inhaled phage therapy.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bacteriophage; Nebulizer; Plaque assay; TEM; Viable respirable fraction

Mesh:

Year:  2018        PMID: 29353018     DOI: 10.1016/j.ejpb.2018.01.010

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  11 in total

1.  Storage stability of inhalable phage powders containing lactose at ambient conditions.

Authors:  Rachel Yoon Kyung Chang; Martin Wallin; Elizabeth Kutter; Sandra Morales; Warwick Britton; Jian Li; Hak-Kim Chan
Journal:  Int J Pharm       Date:  2019-01-31       Impact factor: 5.875

Review 2.  Phage therapy for respiratory infections.

Authors:  Rachel Yoon Kyung Chang; Martin Wallin; Yu Lin; Sharon Sui Yee Leung; Hui Wang; Sandra Morales; Hak-Kim Chan
Journal:  Adv Drug Deliv Rev       Date:  2018-08-07       Impact factor: 15.470

3.  Pharmacokinetics and Time-Kill Study of Inhaled Antipseudomonal Bacteriophage Therapy in Mice.

Authors:  Michael Y T Chow; Rachel Yoon Kyung Chang; Mengyu Li; Yuncheng Wang; Yu Lin; Sandra Morales; Andrew J McLachlan; Elizabeth Kutter; Jian Li; Hak-Kim Chan
Journal:  Antimicrob Agents Chemother       Date:  2020-12-16       Impact factor: 5.191

4.  Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.

Authors:  Yu Lin; Rachel Yoon Kyung Chang; Warwick J Britton; Sandra Morales; Elizabeth Kutter; Jian Li; Hak-Kim Chan
Journal:  Eur J Pharm Biopharm       Date:  2019-08-06       Impact factor: 5.571

Review 5.  Inhaled Delivery of Anti-Pseudomonal Phages to Tackle Respiratory Infections Caused by Superbugs.

Authors:  Hak-Kim Chan; Rachel Yoon Kyung Chang
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2021-12-30       Impact factor: 3.440

6.  Synergy of nebulized phage PEV20 and ciprofloxacin combination against Pseudomonas aeruginosa.

Authors:  Yu Lin; Rachel Yoon Kyung Chang; Warwick J Britton; Sandra Morales; Elizabeth Kutter; Hak-Kim Chan
Journal:  Int J Pharm       Date:  2018-09-14       Impact factor: 5.875

7.  Utility of Three Nebulizers in Investigating the Infectivity of Airborne Viruses.

Authors:  Sadegh Niazi; Lisa K Philp; Kirsten Spann; Graham R Johnson
Journal:  Appl Environ Microbiol       Date:  2021-07-27       Impact factor: 4.792

Review 8.  Prospects of Inhaled Phage Therapy for Combatting Pulmonary Infections.

Authors:  Xiang Wang; Zuozhou Xie; Jinhong Zhao; Zhenghua Zhu; Chen Yang; Yi Liu
Journal:  Front Cell Infect Microbiol       Date:  2021-12-06       Impact factor: 5.293

Review 9.  Clinical Pharmacology of Bacteriophage Therapy: A Focus on Multidrug-Resistant Pseudomonas aeruginosa Infections.

Authors:  Dana Holger; Razieh Kebriaei; Taylor Morrisette; Katherine Lev; Jose Alexander; Michael Rybak
Journal:  Antibiotics (Basel)       Date:  2021-05-11

Review 10.  The COVID-19 Vaccine Race: Challenges and Opportunities in Vaccine Formulation.

Authors:  Jieliang Wang; Ying Peng; Haiyue Xu; Zhengrong Cui; Robert O Williams
Journal:  AAPS PharmSciTech       Date:  2020-08-05       Impact factor: 3.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.